Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movers and Shakers

- PMLiVE

J&J to launch ‘innovation centres’ in US, UK and China

Will target local life sciences partnerships in early-stage innovation

- PMLiVE

Pfizer’s RA drug tofacitinib tops methotrexate in phase III

Trial results back drug as major new treatment in rheumatoid arthritis

Pfizer forms branded generics sales alliance in China

Forms joint venture with local company Hisun

UK flag

Life sciences industry wants more from new UK business strategy

BIA and ABPI welcome measures but tell government more can be done

- PMLiVE

Market access webinar series begins with UK healthcare changes

Experts convene for first Sudler & Hennessey and Kantar Health online event

- PMLiVE

Pfizer’s Andrew Thomas takes up UK comms agency role

Joins London-based Red Door Communications as head of international

Pfizer gets US approval for leukaemia drug Bosulif

FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

- PMLiVE

BIA says crowdfunding scheme could ‘create 1,500 jobs a year’

Wants UK tax concessions for individuals who invest

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

- PMLiVE

End of the line for intravenous bapineuzumab in Alzheimer’s

Negative trial results for Pfizer and Johnson & Johnson to concede defeat

- PMLiVE

Pfizer sells Kent R&D centre to property consortium

Discovery Park Ltd takes over site 18 months after US pharma firm announced plans to exit it

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links